Paul Hastings LLP advised NervGen Pharma Corp. in the transaction. NervGen Pharma Corp. closed its public offering including the full exercise of the underwriters’ over-allotment option...
Standard 1 Year Membership Required
You must be a Standard 1 Year member to access this content.
Already a member? Log in here